These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8359564)

  • 41. Slow intestinal transit and gallstone formation.
    Hussaini SH; Pereira SP; Dowling RH; Wass JA
    Lancet; 1993 Mar; 341(8845):638. PubMed ID: 8094871
    [No Abstract]   [Full Text] [Related]  

  • 42. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U; Quabbe HJ
    Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hepatobiliary and gastrointestinal manifestations of acromegaly.
    Ezzat S
    Dig Dis; 1992; 10(3):173-80. PubMed ID: 1611713
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinical application of somatostatin-analogue].
    Tanaka K; Itoh S; Shimizu N
    Nihon Rinsho; 1990 May; 48(5):1084-8. PubMed ID: 2165538
    [No Abstract]   [Full Text] [Related]  

  • 45. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
    Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
    Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Novel pharmacologic therapies in acromegaly].
    Góth M; Hubina E; Kovács L; Szabolcs I
    Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A prospective multicenter octreotide dose response study in the treatment of acromegaly.
    Ezzat S; Redelmeier DA; Gnehm M; Harris AG
    J Endocrinol Invest; 1995 May; 18(5):364-9. PubMed ID: 7594225
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
    Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The pharmacological aspects of the treatment of acromegaly.
    Giustina A; Zaltieri G; Negrini F; Wehrenberg WB
    Pharmacol Res; 1996; 34(5-6):247-68. PubMed ID: 9076850
    [No Abstract]   [Full Text] [Related]  

  • 50. Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-I, and the amino-terminal propeptide of type III procollagen in acromegaly.
    Salmela PI; Juustila H; Pyhtinen J; Jokinen K; Alavaikko M; Ruokonen A
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1193-201. PubMed ID: 2180976
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Somatostatin analogs in acromegaly.
    Freda PU
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3013-8. PubMed ID: 12107192
    [No Abstract]   [Full Text] [Related]  

  • 52. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.
    Newman CB; Melmed S; Snyder PJ; Young WF; Boyajy LD; Levy R; Stewart WN; Klibanski A; Molitch ME; Gagel RF
    J Clin Endocrinol Metab; 1995 Sep; 80(9):2768-75. PubMed ID: 7673422
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serum ghrelin levels in acromegaly: effects of surgical and long-acting octreotide therapy.
    Freda PU; Reyes CM; Conwell IM; Sundeen RE; Wardlaw SL
    J Clin Endocrinol Metab; 2003 May; 88(5):2037-44. PubMed ID: 12727951
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Emerging indications for octreotide therapy, Part 1.
    Mosdell KW; Visconti JA
    Am J Hosp Pharm; 1994 May; 51(9):1184-92. PubMed ID: 8042637
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.
    Cozzi R; Montini M; Attanasio R; Albizzi M; Lasio G; Lodrini S; Doneda P; Cortesi L; Pagani G
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1397-403. PubMed ID: 16449332
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Proliferation activity in somatotroph pituitary adenomas.
    Delgrange E; Donckier J
    Mayo Clin Proc; 1998 Oct; 73(10):1027-8. PubMed ID: 9787756
    [No Abstract]   [Full Text] [Related]  

  • 57. ANNIVERSARY REVIEW: Octreotide, 40 years later.
    Lamberts SWJ; Hofland LJ
    Eur J Endocrinol; 2019 Nov; 181(5):R173-R183. PubMed ID: 31398712
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biliary colic on abrupt withdrawal of octreotide.
    James RA; Rhodes M; Rose P; Kendall-Taylor P
    Lancet; 1991 Dec; 338(8781):1527. PubMed ID: 1683947
    [No Abstract]   [Full Text] [Related]  

  • 59. Complications of long-acting somatostatin analogue therapy.
    Jackson JA
    Am J Med; 1989 Apr; 86(4):512-3. PubMed ID: 2929652
    [No Abstract]   [Full Text] [Related]  

  • 60. Sandostatin-induced thrombocytopenia.
    Hanna WT; Maull KI
    South Med J; 1990 Jan; 83(1):77. PubMed ID: 2300842
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.